Gilead Sciences, Inc. $GILD Stock Bought by International Assets Investment Management LLC

International Assets Investment Management LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2,702.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 250,000 shares of the biopharmaceutical company’s stock after purchasing an additional 241,080 shares during the quarter. International Assets Investment Management LLC’s holdings in Gilead Sciences were worth $37,262,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Gilead Sciences in the 2nd quarter worth $15,393,785,000. State Street Corp grew its position in shares of Gilead Sciences by 2.3% during the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after buying an additional 1,357,967 shares in the last quarter. Amundi increased its stake in shares of Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after buying an additional 1,018,976 shares during the period. Legal & General Group Plc purchased a new position in shares of Gilead Sciences during the second quarter valued at $1,316,606,000. Finally, Deutsche Bank AG purchased a new position in shares of Gilead Sciences during the second quarter valued at $918,387,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the transaction, the insider owned 113,684 shares of the company’s stock, valued at $17,759,714.48. The trade was a 2.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the transaction, the director owned 12,894 shares of the company’s stock, valued at approximately $1,916,306.28. This trade represents a 58.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 111,000 shares of company stock worth $15,877,860. Insiders own 0.30% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Gilead Sciences Trading Up 3.1%

GILD opened at $170.68 on Friday. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. The firm has a market cap of $211.63 billion, a price-to-earnings ratio of -54.01 and a beta of 0.31. Gilead Sciences, Inc. has a 12 month low of $114.02 and a 12 month high of $175.65. The stock has a fifty day moving average price of $150.87 and a 200-day moving average price of $139.79.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.36. The company had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative return on equity of 1.70% and a negative net margin of 12.47%. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.47 earnings per share. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post -0.48 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on GILD shares. BMO Capital Markets restated an “outperform” rating and issued a $184.00 price objective on shares of Gilead Sciences in a report on Friday. Truist Financial increased their target price on shares of Gilead Sciences from $158.00 to $181.00 and gave the stock a “buy” rating in a report on Friday. Jefferies Financial Group reissued a “buy” rating and set a $185.00 target price on shares of Gilead Sciences in a research report on Friday, October 23rd. Weiss Ratings upgraded shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Finally, UBS Group restated a “buy” rating and issued a $195.00 price target on shares of Gilead Sciences in a report on Friday. Twenty-three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $169.19.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.